Multimodality molecular imaging of the lung.
Lung diseases cause significant morbidity and mortality and lead to high healthcare utilization. However, few lung disease-specific biomarkers are available to accurately monitor disease activity for the purposes of clinical management or drug development. Advances in cross-modal imaging technologies, such as combined positron emission tomography (PET) and magnetic resonance (MR) imaging scanners and PET or single-photon emission computed tomography (SPECT) combined with computed tomography (CT), may aid in the development of noninvasive, molecular-based biomarkers for lung disease. However, the lungs pose particular challenges in obtaining accurate quantification of imaging data due to the low density of the organ and breathing motion. This review covers the basic physics underlying PET, SPECT, CT, and MR lung imaging and presents technical considerations for multimodal imaging with regard to PET and SPECT quantification. It also includes a brief review of the current and potential clinical applications for these hybrid imaging technologies.
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA. Division of Radiological Sciences and Nuclear Medicine, Mallinckrodt Institute of Radiology, Campus Box 8225, 510 S. Kingshighway Blvd, St. Louis, MO 63110, USA.
Delphine L
DL
Chen
Department of Radiology and Bioengineering and Physics, University of Washington Medical Center, Seattle, WA, USA.
Paul E
PE
Kinahan
Lung cancer; Lung disease; Magnetic resonance imaging; Molecular imaging; Multimodality imaging; Positron emission tomography; Single photon emission computed tomography